Literature DB >> 29565474

Implantation of adipose-derived stem cells cures the optic nerve injury on rats through inhibiting the expression of inflammation factors in the TLR4 signaling pathway.

L-J Wang1, L-P Liu, X L Gu, M Wang, L-M Liu.   

Abstract

OBJECTIVE: The use of adipose-derived stem cells (ADSCs) to cure the optic nerve injury was never shown previously. Here, we implanted purified ADSCs into optic nerve injury of rats.
MATERIALS AND METHODS: Male Sprague Dawley (SD) rats were used in this study. The vision degeneration was detected by Flash-visual evoked potential (F-VEP) assay. The expression of Macrophage-1 (Mac-1), myeloid differentiation factor 88 (MyD88), and nuclear transcription factor-κB (NF-κB) were studied by Western blot. The expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-α in the optical nerve lysates were assessed by enzyme-linked immunosorbent assay (ELISA).
RESULTS: We found out that ADSC implantation inhibits the amplitude decrease and latency increase of the P1 wave caused by the optic nerve injury. The expression of the inflammation associated proteins of the toll-like receptor 4 (TLR4) signaling pathway, including Mac-1, MyD88, NF-κB, IL-6, and TNF-α, were inhibited in the ADSC therapy group compared to the control group.
CONCLUSIONS: Our results indicated that ADSC implantation can inhibit the inflammation after the optic nerve injury and improve the functional vision impairment. These findings suggested ADSC implantation as a translational therapy method for optic nerve injury in clinics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29565474     DOI: 10.26355/eurrev_201803_14458

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study.

Authors:  Ayse Oner; Zeynep Burcin Gonen; Duygu Gülmez Sevim; Neslihan Sinim Kahraman; Metin Unlu
Journal:  Int Ophthalmol       Date:  2019-07-15       Impact factor: 2.031

Review 2.  Traumatic optic neuropathy: a review of current studies.

Authors:  Bin Chen; Hengsen Zhang; Qing Zhai; Huaipeng Li; Chunxia Wang; Yong Wang
Journal:  Neurosurg Rev       Date:  2022-01-16       Impact factor: 3.042

Review 3.  Changes in best-corrected visual acuity in patients with dry age-related macular degeneration after stem cell transplantation: systematic review and meta-analysis.

Authors:  Licheng Li; Yang Yu; Shu Lin; Jianmin Hu
Journal:  Stem Cell Res Ther       Date:  2022-06-07       Impact factor: 8.079

4.  Single-Cell Gene Expression Analysis and Evaluation of the Therapeutic Function of Murine Adipose-Derived Stromal Cells (ASCs) from the Subcutaneous and Visceral Compartment.

Authors:  Dominik Pförringer; Matthias M Aitzetmüller; Elizabeth A Brett; Khosrow S Houschyar; Richard Schäfer; Martijn van Griensven; Dominik Duscher
Journal:  Stem Cells Int       Date:  2018-12-11       Impact factor: 5.443

5.  The Antiangiogenic Properties of Adipose-Derived Mesenchymal Stem/Stromal Cells in Corneal Neovascularization in a Rabbit Model.

Authors:  Demetrios Pirounides; Anastasia Komnenou; Nikolaos Papaioannou; Eleni Gounari; Ioanna Stylianaki; Alexandros Alexandridis; Angeliki Chranioti; Evangelia Kofidou; Georgios Koliakos; Vasileios Karampatakis
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2020-03-12

6.  Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nrf2/HO-1 and TLR4/NF-κB signaling pathways.

Authors:  Xiao Huang; Guo-Qiang Fei; Wen-Juan Liu; Jing Ding; Yuan Wang; Hao Wang; Jian-Lin Ji; Xin Wang
Journal:  Acta Pharmacol Sin       Date:  2019-12-03       Impact factor: 6.150

7.  Claudin 14/15 play important roles in early wallerian degeneration after rat sciatic nerve injury.

Authors:  Min Cai; Jian Shao; Yi Wang; Bryant Yung; Jian-Nan Li; Huan-Huan Zhang; Yu-Ting Li; Deng-Bing Yao
Journal:  Chin J Traumatol       Date:  2021-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.